Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.
Saved in:
| Title: | Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. |
|---|---|
| Authors: | Piha-Paul SA; University of Texas MD Anderson Cancer Center, Houston, TX., Hann CL; Johns Hopkins University School of Medicine, Baltimore, MD., French CA; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA., Cousin S; Medical Oncology, Institute Bergonié, Bordeaux, France., Braña I; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Cassier PA; Medical Oncology, Léon Bérard Cancer Center, Lyon, France., Moreno V; Medical Oncology, START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, Spain., de Bono JS; The Institute of Cancer Research and Royal Marsden Hospital, London, UK., Harward SD; GSK, Research Triangle Park, NC., Ferron-Brady G; GSK, Collegeville, PA., Barbash O; GSK, Collegeville, PA., Wyce A; GSK, Collegeville, PA., Wu Y; GSK, Collegeville, PA., Horner T; GSK, Collegeville, PA., Annan M; GSK, Collegeville, PA., Parr NJ; UCB Celltech, Slough, UK., Prinjha RK; Division of Medical Oncology, Ottawa Hospital Cancer Centre, Ottawa, ON, Canada., Carpenter CL; Rubius Therapeutics, Cambridge, MA., Hilton J; Division of Medical Oncology, Ottawa Hospital Cancer Centre, Ottawa, ON, Canada., Hong DS; University of Texas MD Anderson Cancer Center, Houston, TX.; Johns Hopkins University School of Medicine, Baltimore, MD.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.; Medical Oncology, Institute Bergonié, Bordeaux, France.; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.; Medical Oncology, Léon Bérard Cancer Center, Lyon, France.; Medical Oncology, START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, Spain.; The Institute of Cancer Research and Royal Marsden Hospital, London, UK.; GSK, Research Triangle Park, NC.; GSK, Collegeville, PA.; UCB Celltech, Slough, UK.; Division of Medical Oncology, Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.; Rubius Therapeutics, Cambridge, MA.; Abramson Cancer Center at University of Pennsylvania, Philadelphia, PA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Haas NB; Abramson Cancer Center at University of Pennsylvania, Philadelphia, PA., Markowski MC; Johns Hopkins University School of Medicine, Baltimore, MD., Dhar A; GSK, Collegeville, PA., O'Dwyer PJ; University of Texas MD Anderson Cancer Center, Houston, TX.; Johns Hopkins University School of Medicine, Baltimore, MD.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.; Medical Oncology, Institute Bergonié, Bordeaux, France.; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.; Medical Oncology, Léon Bérard Cancer Center, Lyon, France.; Medical Oncology, START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, Spain.; The Institute of Cancer Research and Royal Marsden Hospital, London, UK.; GSK, Research Triangle Park, NC.; GSK, Collegeville, PA.; UCB Celltech, Slough, UK.; Division of Medical Oncology, Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.; Rubius Therapeutics, Cambridge, MA.; Abramson Cancer Center at University of Pennsylvania, Philadelphia, PA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. |
| Source: | JNCI cancer spectrum [JNCI Cancer Spectr] 2019 Nov 06; Vol. 4 (2), pp. pkz093. Date of Electronic Publication: 2019 Nov 06 (Print Publication: 2020). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 101721827 Publication Model: eCollection Cited Medium: Internet ISSN: 2515-5091 (Electronic) Linking ISSN: 25155091 NLM ISO Abbreviation: JNCI Cancer Spectr Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2515-5091 |
|---|---|
| DOI: | 10.1093/jncics/pkz093 |
